Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E17.74 EPS (ttm)15.95 Insider Own0.10% Shs Outstand215.60M Perf Week0.75%
Market Cap61.00B Forward P/E12.54 EPS next Y22.56 Insider Trans26.39% Shs Float211.49M Perf Month1.55%
Income3.48B PEG2.64 EPS next Q4.54 Inst Own90.60% Short Float1.47% Perf Quarter3.66%
Sales11.53B P/S5.29 EPS this Y10.30% Inst Trans0.10% Short Ratio2.01 Perf Half Y9.44%
Book/sh53.24 P/B5.31 EPS next Y10.11% ROA15.90% Target Price319.68 Perf Year8.75%
Cash/sh13.36 P/C21.18 EPS next 5Y6.73% ROE29.50% 52W Range244.28 - 307.33 Perf YTD8.31%
Dividend- P/FCF48.11 EPS past 5Y27.40% ROI21.00% 52W High-7.94% Beta0.78
Dividend %- Quick Ratio2.00 Sales past 5Y17.80% Gross Margin86.60% 52W Low15.82% ATR5.48
Employees7400 Current Ratio2.30 Sales Q/Q3.10% Oper. Margin41.60% RSI (14)65.77 Volatility1.43% 1.88%
OptionableYes Debt/Eq0.57 EPS Q/Q-21.80% Profit Margin30.20% Rel Volume0.63 Prev Close281.44
ShortableYes LT Debt/Eq0.52 EarningsJul 25 BMO Payout0.00% Avg Volume1.55M Price282.92
Recom2.10 SMA202.24% SMA507.11% SMA2004.33% Volume977,840 Change0.53%
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $315
Jun-19-17Upgrade UBS Sell → Neutral $262 → $270
Mar-16-17Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-16-17Downgrade Leerink Partners Outperform → Mkt Perform
Mar-02-17Initiated Instinet Buy $345
Feb-07-17Upgrade Citigroup Neutral → Buy
Dec-29-16Reiterated Raymond James Strong Buy $375 → $386
Dec-09-16Reiterated Stifel Hold $291 → $298
Nov-08-16Initiated Mizuho Buy $290
Nov-07-16Upgrade Piper Jaffray Neutral → Overweight
Nov-07-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-06-16Downgrade Jefferies Buy → Hold
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Jul-21-17 01:38PM  Will Gilead Beat 2Q Earnings? PerhapsBut Does It Matter?
01:15PM  7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods
08:45AM  Biotechs Find Strength In Numbers In Treating Multiple Sclerosis Investor's Business Daily
Jul-19-17 11:50PM  The Best Stock in Massachusetts: Biogen Kiplinger
02:30PM  Biotech Stocks On Verge Of Next Major Move Up Investopedia
09:52AM  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2? Zacks
Jul-18-17 04:16PM  These 2 Drug Giants In Buy Range Just Beat Earnings Views Investor's Business Daily
08:42AM  AveXis Inc.: Buy at the High? Motley Fool
Jul-17-17 02:30PM  'Stars Align' For These Biotechs To Crush Earnings Consensus Investor's Business Daily
01:55PM  Biogen aims to block Tecfidera generics with flurry of lawsuits American City Business Journals
11:15AM  [$$] Biotechs in Focus Ahead of Earnings
Jul-16-17 11:42AM  Better Buy: Biogen Inc. vs. Celgene Corporation Motley Fool
Jul-14-17 02:37PM  Could Q2 Surprise Spike This Beleaguered Biotech's Stock? Investor's Business Daily
10:59AM  Expect A Strong Quarter From Biogen: Instinet
07:30AM  Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®) Business Wire
Jul-13-17 05:54PM  Top Stock Reports for Boeing, AbbVie & U.S. Bancorp Zacks
04:39PM  How Biogen Inc. Makes Most of Its Money Motley Fool
Jul-11-17 10:23AM  3 Red-Hot Biotech Stocks That Could Get Even Hotter
Jul-10-17 02:35PM  What Drove Biogen Stock in 2Q17? Market Realist
02:19PM  Three Biotechs That Look Best Positioned Ahead Of Q2 Earnings
11:31AM  Amgen, Inc. (AMGN) Stock Is the Cure for Ailing Portfolios InvestorPlace
07:30AM  Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs Business Wire
Jul-05-17 01:54PM  Bright spots in biotech CNBC Videos
09:00AM  Why Gilead Stock Is Back in the Game Investopedia
08:03AM  3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher Motley Fool
Jul-03-17 10:14AM  Finding Value in Biotech?
Jul-01-17 11:41AM  4 Reasons the AveXis Inc. Rally Could Continue Motley Fool
Jun-30-17 09:25AM  Can Regeneron Hit $540?
07:36AM  What Analysts Recommend for Biogen in June 2017 Market Realist
Jun-29-17 12:18PM  U.S. IRS probes drug company-funded patient assistance charity Reuters
12:14PM  Seeking Value in Biotech: Bioverativ
10:37AM  Biogens Interferon Therapies Could Witness Modest Fall in 2017 Market Realist
09:08AM  Spinraza May Significantly Boost Biogens Revenue Growth Market Realist
08:40AM  Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod Zacks
07:43AM  Biosimilars Could Boost Biogens Revenue in 2017 Market Realist
07:30AM  New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity Business Wire
Jun-28-17 05:35PM  Tysabri Could Boost Biogens Revenue Growth Market Realist
04:06PM  How Biogens Tecfidera Is Expected to Perform in 2017 Market Realist
02:35PM  Whats in Biogens Clinical Pipeline? Market Realist
07:30AM  Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs Business Wire
07:20AM  Like Biogen, this Fidelity-backed startup is targeting a deadly infant disease American City Business Journals
Jun-27-17 08:08AM  2 Pharma Buyout Targets That May Surprise You Motley Fool
Jun-23-17 09:54AM  Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold Benzinga
07:55AM  Biogens IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use Business Wire
Jun-22-17 04:53PM  Biogen, Inc. Value Analysis (NASDAQ:BIIB) : June 22, 2017 Capital Cube
06:48AM  Futures: These 2 Big Breakouts Highlight New Market Leadership Investor's Business Daily
Jun-21-17 04:26PM  [$$] Pharma recovers composure as price concerns ease Financial Times
04:11PM  Biotech Breakouts: Biogen Spinoff Bioverativ In Buy Zone Investor's Business Daily
03:00PM  Amgen An Undervalued Industry Leader Forbes
10:35AM  Amgen: In Defense of A Pipeline
08:08AM  Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : June 21, 2017 Capital Cube
Jun-20-17 04:01PM  Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017 Business Wire
03:36PM  Updates on the Adcetris and Opdivo Combination Market Realist
11:31AM  Biotech Stock With 50% Profit Margin Nears Buy Zone Investor's Business Daily
07:30AM  Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer Business Wire
07:27AM  5 Most Profitable Big Pharma Stocks on the Market Right Now Motley Fool
Jun-19-17 04:28PM  US STOCKS-Wall St hits record highs on strong technology, health stocks Reuters
03:16PM  The Near-Term Setup For Biogen Has Positive Risk/Reward Written All Over It Benzinga
03:02PM  US STOCKS-Wall St at record highs on technology, health stocks strength Reuters
02:43PM  Biogen's stock jumps after UBS boosts rating, price target MarketWatch
02:15PM  Picks of Steel CNBC Videos
11:52AM  Biogen Upgraded at UBS on Alzheimer's Clinical Trial Progress
11:11AM  Biogen: "The Underperformance Stops Here"
09:02AM  Do You Really Want to Love Your Medicines? Fortune
08:56AM  Morning Movers: Valeant Jumps, U.S. Steel Gains, Biogen Rises
Jun-16-17 01:06PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
Jun-15-17 09:19PM  Accenture, 1QBit partner for drug discovery through quantum computing ZDNet
08:26AM  Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug Zacks
08:02AM  Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects
Jun-14-17 10:10PM  How analysts are interpreting Biogen's management shakeup American City Business Journals
05:46PM  The Hot Stock: Alexion Pharmaceuticals Jumps 9.3%
05:27PM  Biogen and Anadarko slump while H&R Block and Southern rise Associated Press
04:16PM  Is Defecting CFO A Glutton For Punishment By Moving To Alexion? Investor's Business Daily
04:16PM  Alexion Stock Soars After It Poaches Biogen CFO Investopedia
02:02PM  [$$] Alexion Even Stronger After Adding Biogen CFO
01:31PM  One of Stephanie Link's picks jumps 10 percent CNBC Videos
12:22PM  Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data
11:54AM  Biogen: OopsThere Goes Another Executive
10:31AM  Biogen Loses Top Executive Again, CFO Clancy to Join Alexion Zacks
09:15AM  Alexion Pharmaceuticals Adds New CFO From Biogen 24/7 Wall St.
08:31AM  Morning Movers: Alexion Climbs on Biogen Hire; H&R Block Jumps
08:03AM  3 Stocks to Watch on Wednesday: Ford Motor Company (F), Alexion Pharmaceuticals, Inc. (ALXN) and H & R Block Inc (HRB) InvestorPlace
07:30AM  Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations Business Wire
Jun-13-17 06:05PM  Biogen CFO Bolts to Alexion
05:46PM  Alexion names Biogen's Paul Clancy as CFO Reuters
05:05PM  Biogen exodus continues as CFO set to join Alexion American City Business Journals
04:45PM  Alexion hires Biogen executive to serve as its CFO MarketWatch
04:15PM  Biogen Announces Management Change Business Wire
07:24AM  Celgene's Next Blockbuster: What You Need to Know Motley Fool
Jun-12-17 10:37AM  How Ionis Pharmaceuticals Spinraza Performed in 1Q17 Market Realist
Jun-09-17 07:22AM  2 Reasons Why Biogen's Shares Slumped in May Motley Fool
Jun-08-17 11:13AM  Breakout Watch: Top Funds Buy This Biotech IPO With 196% Growth Investor's Business Daily
Jun-07-17 04:33PM  IPO Stock News And Analysis: Find Today's Top New Issues Investor's Business Daily
Jun-06-17 12:28PM  3 Stocks That Could Be Life-Changers Motley Fool
10:13AM  Why Ionis Pharmaceuticals Inc. Swooned 6% in May Motley Fool
Jun-05-17 12:40PM  Is This Biotech IPO And Biogen Spinoff About To Break Out? Investor's Business Daily
Jun-02-17 03:58PM  Biogen/Ionis Spinraza Granted Marketing Authorization in EU Zacks
Jun-01-17 04:15PM  Biogen, Ionis Stocks Pop After Europe Approves $125,000 Drug Investor's Business Daily
09:50AM  Biogen rare infant disease drug Spinraza approved in E.U. American City Business Journals
09:16AM  Bridge With Buffett And Thorp, And Five Stocks That Could Follow Suit Forbes
Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The company's Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkin's lymphoma; and Aducanumab and E2609 for Alzheimer's disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The company's Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecJul 19Sale285.007,7582,211,03027,232Jul 20 05:00 PM
Posner Brian SDirectorJun 09Sale256.311,084277,8406,330Jun 12 04:29 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,25904,027Jun 05 04:38 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,73604,663May 04 04:16 PM
Vounatsos MichelChief Executive OfficerMay 01Buy271.351,402380,4332,927May 02 04:18 PM
DENNER ALEXANDER JDirectorApr 27Buy278.5073,85820,569,476383,858May 01 05:47 PM
Clancy Paul JExecutive VP and CFOApr 25Sale290.009,8922,868,68010,813Apr 27 04:23 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratApr 03Sale274.081,981542,9527,060Apr 04 04:18 PM
Clancy Paul JExecutive VP and CFOMar 13Sale291.559,8912,883,72120,705Mar 14 07:32 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.004810718Mar 03 06:07 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratMar 01Sale290.07973282,2389,041Mar 03 06:02 PM
Clancy Paul JExecutive VP and CFOFeb 28Option Exercise0.006,780031,948Mar 02 05:24 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 28Option Exercise0.004,785010,398Mar 02 05:22 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 28Option Exercise0.005,559036,024Mar 02 05:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 28Option Exercise0.0068104,508Mar 02 05:18 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffFeb 28Option Exercise0.002,06409,237Mar 02 05:16 PM
DiPietro KennethEVP Human ResourcesFeb 28Option Exercise0.005,69608,260Mar 02 05:12 PM
Vounatsos MichelChief Executive OfficerFeb 27Buy285.391,333380,4251,434Mar 01 04:18 PM
PANGIA ROBERT WDirectorJan 09Option Exercise52.225,450284,59922,078Jan 10 04:15 PM
PANGIA ROBERT WDirectorJan 09Sale295.395,4501,609,87616,628Jan 10 04:15 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffDec 01Sale296.534814,2337,360Dec 05 04:34 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 04Sale311.9426281,7287,579Oct 05 04:24 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 03Sale313.00380118,9407,841Oct 04 05:02 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 01Option Exercise0.001,98209,154Oct 04 05:02 PM
DORSA CAROLINEDirectorSep 22Option Exercise53.6427,5701,478,85544,663Sep 26 04:24 PM
DORSA CAROLINEDirectorSep 22Sale314.0027,5708,656,98017,093Sep 26 04:24 PM